Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities
The DOI matches its Crossref record; 80 of the 83 references it cites were found in a registry or an index.
Abstract
The emergence of immune checkpoint inhibitors for solid tumor treatments represents a major oncologic advance. Since the approval of ipilimumab, a cytotoxic T-lymphocyte–associated antigen 4 (CTLA-4) antibody, for the treatment of metastatic melanoma, many drugs, especially those targeting PD-1/PD-L1, have demonstrated promising antitumor effects in many types of cancer. By reactivating the immune system, these immunotherapies have led to the development of new toxicity profiles, also called immune-related adverse events (irAE). IrAEs can involve many organ systems, and their management is radically different from that of cytotoxic drugs; irAEs require immunosuppressive treatments, such as corticoids or TNFα antibody. In addition, the occurrence of irAEs has raised significant questions. Here, we summarize progress that has been made toward answering these questions, focusing on (i) the impact of immunotherapy dose on irAE occurrence, (ii) the correlation between irAE and patient outcome, (iii) the safety of immune checkpoint inhibitors in patients already treated for autoimmune disease, and (iv) the suspected effect on tumor growth of steroids used for the management of irAEs. Clin Cancer Res; 22(18); 4550–5. ©2016 AACR.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Antibody or cell-based immunotherapeutics for cancer carry inherent risks of bystander immune activation, in addition to the effects of treating the intended tumor target [1–5].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [5]
In the citing paper
“Clinical–pathologic correlation in these individuals resulted in valuable observations that may be instructive in understanding mechanisms of immune-induced pathologies, including those of checkpoint inhibitors, CAR-T cells, and infections such as COVID-19, known to target mucosal tissues and cause severe CRS [1, 5, 8, 18, 19].”
From Immune reconstitution and clinical recovery following anti-CD28 antibody (TGN1412)-induced cytokine storm (2021) · cites this paper as [5]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
Schreiber, R. D., Old, L. J., & Smyth, M. J. (2011) · Science · doi:10.1126/science.1203486 · Cited by 6,474 · cited 1×
“, the ability of the immune system to recognize and destroy cancer cells), leading to tumor growth (1).”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198 · cited 1×
“There is no rationale for dose repetition (58), and the optimal treatment duration is unknown because long responders have been observed, raising the question of whether to stop treatment or administer maintenance treatments (80).”
BackgroundPembrolizumab versus Ipilimumab in Advanced Melanoma
Robert, C., Schachter, J., Long, G. V., Arance, A., Grob, J. J., Mortier, L., Daud, A., Carlino, M. S., McNeil, C., Lotem, M., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1503093 · Cited by 5,887 · cited 1×
“Vitiligo has been described in 11% of melanoma patients treated with pembrolizumab (63).”
BackgroundNivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Cancer immunotherapy comes of age
Mellman, I., Coukos, G., & Dranoff, G. (2011) · Nature · doi:10.1038/nature10673 · Cited by 3,893
Research works printed but not linked: 2
- Borghaei, 2015, Nivolumab versus Docetaxel in advanced nonsquamous non–small cell Lung cancer, N Engl J Med, 373, 1627, 10.1056/nejmoa1507643 · DOI · Paper page
- Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti–CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/s1470-2045(15)70076-8 · DOI · Paper page
Cited by
Kumar, V., Chaudhary, N., Garg, M., Floudas, C. S., Soni, P., & Chandra, A. B. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00049 · Cited by 627
Immune checkpoint inhibitor–related dermatologic adverse events
Geisler, A. N., Phillips, G. S., Barrios, D. M., Wu, J., Leung, D. Y. M., Moy, A. P., Kern, J. A., & Lacouture, M. E. (2020) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2020.03.132 · Cited by 480
Phuengkham, H., Ren, L., Shin, I. W., & Lim, Y. T. (2019) · Advanced Materials · doi:10.1002/adma.201803322 · Cited by 306
Nanomaterials for cancer immunotherapy
Song, W., Musetti, S. N., & Huang, L. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.09.017 · Cited by 281
Aide, N., Hicks, R. J., Le Tourneau, C., Lheureux, S., Fanti, S., & Lopci, E. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-018-4171-4 · Cited by 263
Metadata
- Authors
- Cousin, S., & Italiano, A.
- Affiliations
- Institut Bergonié (FR)
- 1Early Phase Trials Unit, Institut Bergonié, Bordeaux, France.
- ORCID
- Cousin, Sophie
- Venue
- Clinical Cancer Research
- Published
- 2016-09-15
- Volume
- 22
- Issue
- 18
- Pages
- 4550-4555
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- OpenAlex
- W2490874882
- Cited by
- 83
- References
- 83
- Citations by year
- 2026: 3 · 2025: 5 · 2024: 6 · 2023: 5 · 2022: 7 · 2021: 6 · 2020: 13 · 2019: 13 · 2018: 9 · 2017: 14 · 2016: 2
- FWCI
- 1.27
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › Immunotoxicology and immune responses
- Keywords
- immune checkpoint inhibitors, immune-related adverse events, CTLA-4, PD-1/PD-L1, ipilimumab, immunotherapy toxicity, immunosuppressive therapy, corticosteroids, TNF-alpha inhibitors, autoimmune disease, patient outcomes, tumor growth
- MeSH terms
- Antineoplastic Agents, Immunological, Animals, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Humans, Neoplasms, Biomarkers, Tumor, Signal Transduction, Treatment Outcome, Immunomodulation, Molecular Targeted Therapy, B7-H1 Antigen, CTLA-4 Antigen, Programmed Cell Death 1 Receptor
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-15-2569
- The paper
- Cousin, S., & Italiano, A. (2016). Molecular Pathways: Immune Checkpoint Antibodies and their Toxicities. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-15-2569
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.